ChemoCentryx
Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Launch date
Employees
Market cap
€3.4b
Enterprise valuation
€3.2b (Public information from Nov 2022)
Share price
$51.99 CCXI
San Carlos California (HQ)
Authorizing premium user...